CCL5 and prostate carcinoma: Therefore, our finding not only identified CCL5 as a potential biomarker for prostate cancer prognosis and metastasis but also suggested that targeting TAMs/CCL5 may represent a potential clinically available strategy for inhibiting PSCSs and prostate cancer metastasis.